The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field
A decade of disasters in Alzheimer’s R&D over the last 10 years — topped by the disastrous and perhaps final fumble on the amyloid beta line by Biogen — has done little to change biopharma’s appetite for risky clinical development programs. But it has started to alter the selection of preclinical appetizers mainstream players are ordering these days.
We asked Chris Dokomajilar, the founder of DealForma, to run the numbers on Alzheimer’s deals dating back a decade. And what he found may surprise you.
Last year was by far the busiest on record for new Alzheimer’s deals, just as big plays by Merck, Lilly and Roche were all headed to the same rocks that have claimed virtually everything floated against this disease in the last decade. Out of the 126 pacts he tracked over the distance, 27 were struck in 2018. And 6 of the top 10 research deals of the decade — calculated by a total of upfronts and milestones — were all inked last year.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.